Related Experiment Video
Updated: Mar 11, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Antiplatelet Therapy for Secondary Prevention After Acute Myocardial Infarction
Ilaria Cavallari1, Marc P Bonaca1
1TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, 350 Longwood Avenue, Boston, MA 02115, USA.
Insights
Patients with a history of myocardial infarction (MI) benefit from intensive antiplatelet therapy for secondary prevention, but increased bleeding risk necessitates careful patient selection and shared decision-making for optimal outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Patients with prior myocardial infarction (MI) face a sustained elevated risk of subsequent ischemic events.
- Long-term secondary prevention strategies are crucial for managing this high-risk population.
Purpose of the Study:
- To evaluate the benefits and risks of intensive antiplatelet strategies in patients with a history of MI.
- To guide clinicians in individualizing therapy based on patient characteristics and risk scores.
Main Methods:
- Review of large randomized controlled trials (RCTs) assessing antiplatelet therapies.
- Analysis of clinical characteristics, treatment adherence, and integrated risk scores.
Main Results:
- Intensive antiplatelet strategies significantly reduce cardiovascular death, recurrent MI, and stroke.
- These benefits are associated with a notable increase in bleeding risk.
Conclusions:
- Careful patient selection and shared decision-making are essential to balance the benefits and bleeding risks of intensive antiplatelet therapy.
- Clinical factors and risk scores can assist in tailoring treatment for secondary prevention in post-MI patients.
Abstract:
Patients with prior myocardial infarction (MI) are at long-term heightened risk for recurrent ischemic events. Several large randomized controlled trials have demonstrated the benefit of more intensive antiplatelet strategies for long-term secondary prevention of cardiovascular death, recurrent MI, and stroke in patients with a history of MI at a cost of increased bleeding. The bleeding risk associated with long-term intensive antiplatelet strategies requires careful patient selection and involvement of patients in shared decision making regarding risks and benefits of therapy. Clinical characteristics, adherence to therapy, and integrated risk scores may aid clinicians in translating clinical trials into individualized therapy.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Angina IV: Management
01:26Atherosclerosis III: Management